HTA23 Restrictions and Real-World Evidence Requirements in the Health Technology Assessment of Gene Therapy Medicinal Products in Europe, Canada, Australia, and the United States
Abstract
Authors
E Hubscher L Wiltshire HHI Young A Brackley S Ko